Brain Perfusion Follow-Up in Alzheimers Patients During Treatment with Acetylcholinesterase Inhibitors
Flavio Nobili, MD1,
Malick Koulibaly, PhD2,
Paolo Vitali, MD1,
Octave Migneco, MD2,
Giuliano Mariani, MD3,
Klaus Ebmeier, MD4,
Alberto Pupi, MD5,
Philippe H. Robert, MD, PhD6,
Guido Rodriguez, MD1 and
Jacques Darcourt, MD, PhD2
1 Clinical Neurophysiology, Department of Internal Medicine, University of Genoa, Genoa, Italy
2 Nuclear Medicine Department, Laboratory of Biophysics, Centre Antoine Lacassagne, University of Nice, Sophia Antipolis, France
3 Nuclear Medicine, Department of Internal Medicine, University of Genoa, Genoa, Italy
4 Department of Psychiatry, University of Edinburgh, Edinburgh, United Kingdom
5 Department of Physiopathology, University of Florence, Florence, Italy
6 Memory Center, Federation of Clinical Neuroscience, CHU-University of Nice, Sophia Antipolis, France

View larger version (44K):
[in a new window]
|
FIGURE 1. (A) z map of decreased rCBF on repeated SPECT examination (t1) compared with baseline examination (t0) in AD nS subgroup. Significant areas (shown as glass brain in upper part and colored areas superimposed on standard 3-dimensional anatomic template [3D render] in lower part) are found at t1 in frontal, temporal, and parietal superficial cortex in right hemisphere and in frontal and mesial temporal cortex in left hemisphere. Left thalamus and right cerebellar lobe are involved to some extent. Maximum difference is found in right precuneus at level of occipital lobe (BA 31) (z = 6.36; corrected P < 0.001 at cluster level; peak Talairach (23) coordinates: 17, -63, 22). (B) z map of decreased rCBF in nS subgroup compared with S subgroup at t1. Significant area is found in left frontal cortex (maximum difference in middle frontal gyrus (BA 11) (z = 3.92; corrected P = 0.02 at cluster level; peak Talairach (23) coordinates: -28, 44, -11). Other details as in A.
|
|
Copyright © 2002 by the Society of Nuclear Medicine.